🔗 Share this article

The first new treatments for gonorrhoea in a generation are being hailed as a "huge turning point" in the fight against increasingly resistant strains of the bacteria, according to health experts.

A Worldwide Health Concern

Gonorrhoea infections are escalating around the world, with estimates suggesting over 82 million new cases each year. Particularly high rates are reported in Africa and countries within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. Within England, cases have reached a historical peak, while infection numbers across Europe in 2023 were triple the level compared to the rates from 2014.

“The clearance of new treatments for gonorrhoea is an important and timely development in the context of growing infection rates, the spread of superbugs and the extremely scarce treatment choices at this time.”

Health officials are particularly alarmed about the rise in drug-resistant strains. The WHO has listed it as a "critical concern". Ongoing monitoring showed that resistance to key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Treatment Options Receive Clearance

One new antibiotic, marketed under the name a brand name, was authorized by the American regulatory agency in December for treating gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Researchers hope that focused deployment of this new drug will help delay the emergence of superbugs.

Another new antibiotic, created by the pharmaceutical company GSK, also received approval in close succession. This treatment, which is employed against UTIs, was demonstrated in studies to be successful in treating superbug versions of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment was the result of a new, not-for-profit approach for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company Innoviva to develop it.

“This milestone marks a major breakthrough in the therapy of multidrug-resistant gonorrhoea, which until now has been staying ahead of medical innovation.”

Testing Data and Global Access

Based on data published in a major medical journal, the new drug cured over nine in ten of uncomplicated infections. This establishes an similar efficacy with the current standard treatment, which uses two antibiotics. The trial included over 900 volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, the non-profit has the authority to license and sell the drug in many regions with limited resources.

Clinicians on the front lines have voiced optimism. The availability of a single-dose, oral treatment of this kind is seen as a "revolutionary step" for managing the epidemic. This is viewed as vital to lessen the impact of the disease for individuals and to halt the transmission of extremely resistant gonorrhoea worldwide.